Trends and Disparities in Cardiovascular Disease in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease
Open Access
- 13 April 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 956
Abstract
Background/Objectives: Recently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Through analysis of the trends and disparities regarding cardiovascular disease (CVD) among individuals with MASLD, identifying the leading cause of death in this population is crucial. Methods: We conducted a cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) III (1988–1994) and NHANES 2017–2020 data. MASLD was identified by using clinical profiles and liver ultrasonography to exclude other liver diseases. We estimated the prevalence of CVD among individuals with MASLD and calculated the prevalence ratios for those with and without MASLD. Results: In 2017–2020, MASLD affected 31.2% or 61.9 million US adults, and 17.0% (95% confidence interval: 13.7–20.3%) of these individuals had CVD. The absolute CVD prevalence in individuals with MASLD doubled from that in the NHANES III cohort, which was 8.7% (6.4%, 10.9%). These increases were especially notable among older adults, non-Hispanic whites, and those with higher education and income. Individuals with MASLD had a higher prevalence of total CVD than those without MASLD, even after adjusting for socioeconomic and metabolic factors. These differences were more pronounced in younger age groups. Conclusions: This study revealed a doubled 30-year trend in CVD prevalence among adults with MASLD in the US. Sociodemographic disparities emphasize the need for tailored screening, prevention, and policy measures to address gaps and promote cardiovascular health in this population.Keywords
Funding Information
- Hubei key laboratory opening project (2021KFY018)
This publication has 44 references indexed in Scilit:
- Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020JAMA Cardiology, 2023
- Trends in the Prevalence of Stroke Among Community-Dwelling Individuals in the US, 1999-2018JAMA Neurology, 2023
- Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysiseClinicalMedicine, 2022
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical SettingsEndocrine Practice, 2022
- Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver diseaseDigestive and Liver Disease, 2021
- Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018JAMA, 2021
- Trends in Cardiovascular Disease Prevalence by Income Level in the United StatesJAMA Network Open, 2020
- Trends in Prescription Medication Use Among Children and Adolescents—United States, 1999-2014JAMA, 2018
- Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015JACC, 2017
- The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy IssuesJACC, 2012